Anavex Life Sciences Corp (AVXL)

[RedShoulder]

Exactly 4 months left in the year and 7 catalysts to achieve:

1. Top-line data ANAVEX®2-73-AD-004: Potentially pivotal Phase 2b/3 AD clinical trial – expected fall 2022

2. Data of 48-week OLE PDD Phase 2 study – expected by end 2022

3. EXCELLENCE completion: Potentially pivotal Phase 2/3 pediatric RTT clinical trial – expected by end 2022

4. Initiation of ANAVEX®2-73 imaging-focused Parkinson’s disease clinical trial – expected 2022

5. Initiation of potentially pivotal ANAVEX®2-73 Phase 2/3 Fragile X clinical trial – expected 2022

6. Initiation of potentially pivotal ANAVEX®2-73 Phase 2/3 clinical trial for the treatment of a new, rare disease indication – expected 2022

7. Initiation of ANAVEX®3-71 Phase 2 clinical trial for FTD, schizophrenias and Alzheimer’s disease – expected 2022

Pazzo thanks for the 2022 list as a reminder of how much will be PRed before the end of this year in just 4 months.

Every time Anvex has had a PR the shorts pile on taking the potential gains away. The successful Rett Avatar trial is an excellent example and one the has had lasting effects in suppressing the SP to the present time. Some of that was foot shooting as in not PRing the Rett Avatar change to phase 3 late last year when it was desperately needed; and the damage to the good Avatar Rett trial results by not PRing the change on how the data was going to be evaluated when the change was made last year; giving AF an easy target.

I think it is obvious that he will be stacking the deck against the shorts by intentional spacing out these 7 items for maximum effect before the year ends for the desired effect of forced covering when the pain becomes unbearable for the shorts.

Fall starts later this month. Anavex fireworks in the last quarter,